Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells

Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells

Vγ2Vδ2 T cell-based immunotherapy has benefited some patients in clinical trials, but the overall efficacy is low for solid tumor patients. In this study, a bispecific antibody against both PD-L1 and CD3 (PD-L1 x CD3), Y111, could efficiently bridge T cells and PD-L1 expressing tumor cells. The Y111...

Full description

Bibliographic Details
Main Authors: Rui Yang, Susu Shen, Cheng Gong, Xin Wang, Fang Luo, Fengyan Luo, Yang Lei, Zili Wang, Shasha Xu, Qian Ni, Yan Xue, Zhen Fu, Liang Zeng, Lijuan Fang, Yongxiang Yan, Jing Zhang, Lu Gan, Jizu Yi, Pengfei Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Immunology
Subjects:
[CD3xPD-L1]
Vγ2Vδ2 T cells
adoptive transfer
immunotherapy
NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.654080/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.654080/full

Similar Items